Pricing and reimbursement of drugs in Sweden

被引:9
|
作者
Lundkvist J. [1 ,2 ]
机构
[1] Stockholm HealthEconomics Consulting, Uppsala
[2] Stockholm HealthEconomics Consulting, 75318 Uppsala
关键词
Drug cost; Health care systems; Pricing; Reimbursement;
D O I
10.1007/s10198-001-0094-1
中图分类号
学科分类号
摘要
The Swedish public health care system is financed mainly by taxes. The major part of drug costs is paid by the drug reimbursement system. Sweden has, as most other countries, seen a large increase in the expenditures on drugs in recent years. The responsibility for the cost of drugs in Sweden has recently been decentralized to the county council level. The reimbursement system of drugs currently covers all drugs with a price approved by the National Social Insurance Board, unless the government specifically decides against such coverage. Two groups of drugs were recently excluded from coverage: drugs for obesity and impotence. The price level of drugs in Sweden is close to the average of the European countries. Economic evaluations are currently not mandatory in Swedish price and reimbursement negotiations but are nonetheless important, particularly in negotiations for drugs expected to command large price premiums. The Swedish pricing and reimbursement system has recently been under investigation, and new reforms are expected in the near future. © Springer-Verlag 2002.
引用
收藏
页码:66 / 67
页数:1
相关论文
共 50 条
  • [1] PRICING AND REIMBURSEMENT OF PHARMACEUTICALS IN SWEDEN
    JONSSON, B
    PHARMACOECONOMICS, 1994, 6 : 51 - 60
  • [2] Pricing and reimbursement of drugs in Ireland
    Barry M.
    Tilson L.
    Ryan M.
    The European Journal of Health Economics, formerly: HEPAC , 2004, 5 (2): : 190 - 194
  • [3] Pricing and reimbursement of drugs in Denmark
    K. Møller Pedersen
    The European Journal of Health Economics, 2003, 4 (1) : 60 - 65
  • [4] Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden
    Jana Davidova
    Lenka Praznovcova
    Cecilia Stålsby Lundborg
    Pharmacy World & Science, 2008, 30 : 57 - 64
  • [5] Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden
    Davidova, Jana
    Praznovcova, Lenka
    Lundborg, Cecilia Stalsby
    PHARMACY WORLD & SCIENCE, 2008, 30 (01): : 57 - 64
  • [6] Pricing and reimbursement of orphan drugs in Italy
    Lopatriello, S.
    Schivazappa, C.
    Negrini, C.
    Berto, P.
    VALUE IN HEALTH, 2006, 9 (06) : A208 - A209
  • [7] REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN
    Cheng, C. Y.
    Chan, H. W.
    Fang, C. H.
    VALUE IN HEALTH, 2019, 22 : S856 - S856
  • [8] PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA
    Kumar, J.
    Bachman, E. M.
    VALUE IN HEALTH, 2011, 14 (03) : A29 - A29
  • [9] THE CONFIDENTIALITY REGARDING DRUGS PRICING AND REIMBURSEMENT IN ROMANIA
    Paveliu, M. S.
    Radu, P.
    VALUE IN HEALTH, 2018, 21 : S87 - S87
  • [10] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317